MedTrace Logo

Volumetric Analysis of Bone Following Jaw Cysts Enucleation With and Without Alb-PRF

NCT05658900 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2022-12-21

No results posted yet for this study

Summary

Cyst is the main cause for longstanding swelling in the mandible or the maxilla, its enlargement usually results in resorption and weakening of bone. Thus the treatment of the cysts is essential to preserve the bone and the adjacent vital structures. Healing of the bone defect and its surrounding soft tissues is a critical issue that needs concerns. Although the Platelet rich fibrin has promising effects in wound healing, it can resorb during 10-14 days. Thus a new autologous platelet concentrate is introduced by Kawasi et al that can remain stable for 4-6 months called albumin PRF.

Conditions

  • Jaw Cysts

Interventions

OTHER

Enucleation with albumin PRF

The protocol that will be used in the preparation of albumin PRF 1. A sample of venous blood, at ten milliliters, at least will be drawn from the patient in a sterile centrifuge tube. 2. The venous blood sample will be centrifuged at 700 g for 8 minutes. \* Betadine: Povidone-iodine, 7.5% (0.75% available iodine), Purdue Products L.P 3. The platelet-poor plasma layer will be taken and heated at uniform temperature 75 celsius for 10 minutes in a thermostatic water bath incubator to denature albumin protein forming albumin gel. 4. Once the albumin gel is cooled, to room temperature for 10 minutes, it will be mixed with the buffy coat layer of PRF using 3 way stop cock and 2 plastic syringes with Luer lock to obtain albumin PRF then leave it in the dappen dish for 5 minutes.

OTHER

Enucleation without albumin PRF

The full-thickness mucoperiosteal flap will be performed using blade no. 15 and Bard- Parker handles extending one tooth anterior and one tooth posterior to the cystic cavity. The mucoperiosteal flap will be reflected using the periosteal elevator to expose the bone. Removal of the overlying bone to expose the cystic lesion. Enucleation of the cyst.

Sponsors & Collaborators

  • Hams Hamed Abdelrahman

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-05-19
Primary Completion
2023-03-09
Completion
2023-03-09

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05658900 on ClinicalTrials.gov